Elan Corporation

Pharmaceutical company

7/26/2008 20:21 ET

Site Map | Contact Us | Search:

Elan News: 2004

28th December 2004

Elan Receives FDA Approval for PRIALT (Ziconotide Intrathecal Infusion) for Severe Chronic Pain

21st December 2004

Biogen Idec and Elan Announce Head-to-Head Study Comparing Safety and Efficacy of TYSABRI® to Rebif®

30th November 2004

Elan Announces Completion of Tender Offer and Consent Solicitation for EPIL III Series B and C Guaranteed Notes

23rd November 2004

FDA Grants Accelerated Approval of TYSABRI®, Formerly ANTEGREN, For the Treatment of Multiple Sclerosis

18th November 2004

PRIALT -Ziconotide- Receives Positive CHMP Recommendation for Intrathecal Treatment of Severe Chronic Pain

17th November 2004

Elan Announces Completion of Offering of US$1.15 Billion Aggregate Principal Amount of Senior Notes

17th November 2004

Elan Announces Receipt of Consents and Tenders for 90% of EPIL III Series B and C Guaranteed Notes

12th November 2004

Elan and Mayo Announce Settlement of Patent Suit Involving Alzheimer's Disease Research

11th November 2004

Elan Announces Pricing of US$1.15 Billion Aggregate Principal Amount of Senior Notes

11th November 2004

Elan Announces Receipt of Requisite Consents in Tender Offer and Consent Solicitation for EPIL III Series B and C Guaranteed Notes

10th November 2004

Elan to Present at SG Cowen & Co. 5Th Annual Global Healthcare Conference

8th November 2004

ANTEGREN One-Year Data from Phase III AFFIRM Study Showed Compelling Results in Meeting Primary Endpoint in Multiple Sclerosis

3rd November 2004

Richard T. Collier to Join Elan as Executive Vice President and General Counsel

2nd November 2004

Elan Announces Intention to Provide Additional Guarantees of Its Outstanding 7.25% Senior Notes

1st November 2004

Biogen Idec and Elan Announce Webcast to Discuss Antegren Accounting

28th October 2004

Elan Announces Partial Cash Tender Offer and Consent Solicitation

28th October 2004

Elan Announces Proposed Offering of Senior Notes

28th October 2004

Elan Reports Third Quarter 2004 Financial Results

25th October 2004

Elan Announces Agreement to Settle Shareholder Class Action; Elan Reaches Provisional Agreement to Settle SEC Investigation

18th October 2004

Elan Dismisses Merger Speculation

14th October 2004

Elan Announces Webcast of Third Quarter 2004 Financial Results

4th October 2004

Elan to File Interim Six Month Irish GAAP Financials with the Dublin and London Stock Exchanges; Interim Results to Include a Reserve for Shareholder Lawsuit and SEC

29th September 2004

Elan and Biogen Idec Submit Application to the European Medicines Agency for Approval of ANTEGREN for Crohn's Disease

22nd September 2004

Elan and Wyeth Receive Patents Supporting Alzheimer's Disease Immunotherapy Treatments

7th September 2004

Elan to Present at the Bear Stearns 17th Annual Healthcare Conference

17th August 2004

Biogen Idec and Elan Announce Update on Global Filings and Data Release for ANTEGREN® for Multiple Sclerosis

29th July 2004

Elan Reports Second Quarter 2004 Financial Results

26th July 2004

FDA Accepts Biologics License Application for ANTEGREN for Multiple Sclerosis

21st July 2004

Elan and Wyeth Announce Results from Phase IIa Clinical Trial of AN-1792

14th July 2004

Elan and Wyeth Receive Patents in Alzheimer's Immunotherapy; New patents further demonstrate the companies' leadership in immunotherapy research

12th July 2004

Elan Announces Webcast of Second Quarter Financial Results

7th July 2004

Elan Announces Webcast of Data from Its Alzheimer's Immunotherapy Programme to Be Presented at the 9th International Conference on Alzheimer's Disease

7th July 2004

Elan Sells Its Myobloc Rights to Solstice Neurosciences Inc

29th June 2004

Elan Announces Repayment by EPIL II of $450 Million Notes at Maturity

28th June 2004

Elan Files Amendment to New Drug Application for Prialt for Severe Chronic Pain Based on Additional Efficacy and Safety Data

28th June 2004

FDA Designates Antegren Biologics License Application for Priority Review as a Treatment for Multiple Sclerosis; Application Under Accelerated Approval Guidelines

17th June 2004

Elan Holds Its AGM, All Resolutions Passed

17th June 2004

Elan Announces Key Strategic Hires

10th June 2004

Elan Announces Manufacturing Agreement with Lilly

4th June 2004

Biogen Idec and Elan Submit Application to the European Medicines Agency for Approval of ANTEGREN for Multiple Sclerosis Based on One-Year Data

3rd June 2004

Elan Announces Webcast of Annual General Meeting on June 17, 2004

25th May 2004

Biogen Idec and Elan Submit Biologics License Application to the FDA for Approval of Antegren for Multiple Sclerosis Based on One-Year Data

18th May 2004

Elan Completes Sale of Frova to Vernalis

18th May 2004

Elan and Biogen Idec Announce Intention to Submit ANTEGREN for Approval for Crohn's Disease in Europe

18th May 2005

Elan and Biogen Idec Announce Results from Phase III Maintenance Trial of ANTEGREN in Crohn's Disease at Digestive Disease Week

17th May 2004

Elan to Sponsor the 9th International Conference on Alzheimer's Disease

13th May 2004

Elan Reports First Quarter 2004 Financial Results

7th May 2004

Elan and Biogen Idec Announce Webcast of ANTEGREN ENACT-2 Maintenance Data to Be Presented at DDW on May 19, 2004

29th April 2004

Elan Sets Date of May 13 for First Quarter 2004 Financial Results, and June 17 for the Annual General Meeting; Elan Announces Filing of 2003 Annual Report on Form 20-F with SEC

27th April 2004

Elan Completes Sale of Zonegran to Eisai

21st April 2004

Elan to Present at the Morgan Stanley Second Annual Global Healthcare Unplugged Conference

21st April 2004

Elan Licenses Its NanoCrystal Technology to Roche

30th March 2004

Elan Announces Strategic Transaction; Eisai to Purchase Elan's Interests in Zonegran in North America and Europe

30th March 2004

Elan Announces Agreement with Vernalis Regarding North American Rights for Frova

23rd March 2004

Biogen Idec and Elan Announce Intention to Submit Antegren for Approval for Multiple Sclerosis in Europe

8th March 2004

Elan Series Z Warrants; Elan Reiterates Terms of Series Z Warrants

4th March 2004

Elan to Present at the SG Cowen 24th Annual Healthcare Conference

25th February 2004

Elan to Present at the Lehman Brothers Seventh Annual Global Healthcare Conference

18th February 2004

Elan Reports Fourth Quarter 2003 and Full-Year Financial Results; Elan Provides Financial Guidance for 2004; Execution Momentum Continues with Key R&D Milestones

18th February 2004

Biogen Idec and Elan Announce Intention to Submit ANTEGREN for Approval for Multiple Sclerosis Based on One-Year Data

16th February 2004

Executive Vice President Seamus Mulligan Leaving Elan upon Successful Completion of Recovery Plan; Elan Executive Helped Company Exceed Asset Divestiture and Joint Venture Goals

12th February 2004

Elan Completes Sale of European Sales and Marketing Business for $120 Million; Transaction Marks Successful Completion of Recovery Plan

3rd February 2004

Elan and Biogen Idec Announce Initiation of ANTEGREN Rheumatoid Arthritis Trial; Phase II Study to Begin First Half Of 2004

29th January 2004

Elan and Biogen Idec Announce Webcast of ANTEGREN -natalizumab- Phase III Maintenance Data in Crohn's Disease

29th January 2004

Elan and Biogen Idec Announce ANTEGREN -Natalizumab- Phase III Maintenance Trial in Crohn's Disease Met Its Primary Endpoint

26th January 2004

Elan Announces Webcast of Fourth Quarter and Full Year 2003 Financial Results

21st January 2004

Elan Announces Continued Progress

12th January 2004

Elan to Present at The JP Morgan HealthcareConference

7th January 2004

Elan Announces Webcast of Positive Prialt Phase III Trial Results

7th January 2004

Elan Achieves Primary Endpoint in Prialt Phase III Trial; Amendment to New Drug Application Expected to Be Filed with U.S. Food and Drug Administration in Second Quarter

Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use